Tumour-infiltrating lymphocyte (TIL) therapy have been a stable of cell therapy for many years and how recently shown clinical effect in phase III studies. How are TILs made, what are the major challenges the therapy face, and what’s next?
In this episode we are joined by Dr Özcan Met, an associated professor at Herlev og Gentofte Hospital, Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital and Technical University Denmark, who is at the forefront of TIL research.
In the episode we discuss how Dr Met and his colleagues are marrying advanced CRISPR edits with TIL therapy to knock-out PD-1, and what’s next for the field. The articles we discuss are:
2. 'Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy’ by Chamberlain CA et al, Mol Therapy Oncolytics, 2022 (
https://pubmed.ncbi.nlm.nih.gov/35141398/).
What is The Cell Therapy Podcast?
Join Gilead-Kite surfing into the future of cell therapy. Listen to Nordic researchers discuss perspectives and future promise of CAR-T in haemato-oncology and solid tumours, CAR-T, TCR, CAR-NK, allo-CAR development and the exciting future of immuno-oncology to combat cancer.
Innehållet i podden är skapat av Gilead Sciences Sweden AB, Hemvärnsgatan 9, 171 54 Solna.